BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 18383425)

  • 1. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
    Chou S
    Rev Med Virol; 2008; 18(4):233-46. PubMed ID: 18383425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.
    Chou S; Wechel LC; Marousek GI
    J Infect Dis; 2007 Jul; 196(1):91-4. PubMed ID: 17538888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
    Drew WL; Miner RC; Marousek GI; Chou S
    J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.
    Sánchez Puch S; Ochoa C; Carballal G; Zala C; Cahn P; Brunet R; Salomón H; Videla C
    J Clin Virol; 2004 Jul; 30(3):271-5. PubMed ID: 15135748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir.
    Chou S; Waldemer RH; Senters AE; Michels KS; Kemble GW; Miner RC; Drew WL
    J Infect Dis; 2002 Jan; 185(2):162-9. PubMed ID: 11807689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance.
    Göhring K; Mikeler E; Jahn G; Rohde F; Hamprecht K
    Antivir Ther; 2008; 13(3):461-6. PubMed ID: 18572760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.
    Boutolleau D; Burrel S; Agut H
    Antiviral Res; 2011 Jul; 91(1):32-5. PubMed ID: 21570426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
    Chou S
    Antimicrob Agents Chemother; 2009 Jan; 53(1):81-5. PubMed ID: 18981262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
    Chou S; Marousek GI
    J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation.
    Sanchez Puch SI; Mathet VL; Porta M; Cuestas ML; Oubiña JR; Videla CM; Salomón HE
    Antiviral Res; 2009 Nov; 84(2):194-8. PubMed ID: 19712701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay.
    Eckle T; Jahn G; Hamprecht K
    J Clin Virol; 2004 May; 30(1):50-6. PubMed ID: 15072754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.
    Chou S; Hakki M; Villano S
    Antiviral Res; 2012 Aug; 95(2):88-92. PubMed ID: 22664236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
    Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
    J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.
    Chou S; Watters M; Sinha R; Kleiboeker S
    Antiviral Res; 2021 Sep; 193():105139. PubMed ID: 34273445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
    James SH; Hartline CB; Harden EA; Driebe EM; Schupp JM; Engelthaler DM; Keim PS; Bowlin TL; Kern ER; Prichard MN
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4682-91. PubMed ID: 21788463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.
    Chou S; Ercolani RJ; Marousek G; Bowlin TL
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3375-9. PubMed ID: 23650173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir.
    McGregor A; Choi KY; Cui X; McVoy MA; Schleiss MR
    Antiviral Res; 2008 Jun; 78(3):250-9. PubMed ID: 18325607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir.
    Foulongne V; Turrière C; Diafouka F; Abraham B; Lastere S; Segondy M
    Acta Virol; 2004; 48(1):51-5. PubMed ID: 15230476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple ganciclovir-resistant strains in a newborn with symptomatic congenital human cytomegalovirus infection.
    Campanini G; Zavattoni M; Cristina E; Gazzolo D; Stronati M; Baldanti F
    J Clin Virol; 2012 May; 54(1):86-8. PubMed ID: 22381918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent and persistent cytomegalovirus infection in a kidney recipient caused by the L595S mutation in UL97 phosphotransferase gene.
    Peixoto M; Mascarenhas L; Cunha A; Dutra M; Miranda E; Silva I; Costa S; Galvão B; Cunha A
    Antivir Ther; 2012; 17(3):585-8. PubMed ID: 22293247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.